Gallium-68-labeled fibroblast activation protein inhibitor-46 PET in patients with resectable or borderline resectable pancreatic ductal adenocarcinoma: A phase 2, multicenter, single arm, open label non-randomized study protocol.
<h4>Background</h4>Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease prone to widespread metastatic dissemination and characterized by a desmoplastic stroma that contributes to poor outcomes. Fibroblast activation protein (FAP)-expressing Cancer-Associated Fibroblasts (CAFs) are crucial co...
Na minha lista:
| Principais autores: | , , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Public Library of Science (PLoS)
2023-01-01
|
| Serier: | PLoS ONE |
| Online adgang: | https://doi.org/10.1371/journal.pone.0294564 |
| Tags: |
Ingen Tags, Vær først til at tagge denne postø!
|
